NOKOMIS, Fla.--(BUSINESS WIRE)--Another high-profile piece of reporting on the Bio-Assembler, a 3-D cell culturing system being developed and marketed by Rainbow Coral Corp. (OTCBB:RBCC) and Nano3D Biosciences (n3D), was published today: this time in Nature Protocols, an online journal of laboratory protocols for bench researchers.
To read the detailed article, please visit www.nature.com/nprot/index.html.
As part of the joint venture’s aggressive marketing push, the Bio-Assembler has now been featured in three recent articles published by the preeminent scientific journal Nature, including a review in Nature Reviews Cancer on the influence of microgravity on cell biology and a product profile on Nature.com. Widely read by researchers and scientists, Nature and its associated periodicals have already given the Bio-Assembler a big boost in name recognition among biotech professionals.
“The Bio-Assembler is the most promising cell-culturing innovation on the market right now, and the Nature pieces have been invaluable in spreading the word about this device to researchers, laboratories and investors,” said RBCC CEO Patrick Brown. “If the Bio-Assembler wasn’t such an incredibly groundbreaking tool, it wouldn’t be enjoying this caliber of coverage. We’re very proud of this product and it’s extremely gratifying to see word of its amazing capabilities spread.”
Rainbow Biosciences is dedicated to the marketing and development of new medical and research technology innovations designed to help capture a growing share of a booming biotech industry alongside Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN).
For more information on RBCC’s partnership with n3D and other biotech initiatives, please visit www.rainbowbiosciences.com/investors.html.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.